Solid Tumor Clinical Trial
Official title:
The Good Patient Study
Adolescents with cancer weigh multiple influences in medical decision-making, including
their own best interest, the perceived wishes of family members, and the interpreted
preferences of the health care team. Parents of children with cancer often describe
themselves as trying to be a good parent in making decisions in the child's best interest.
Adolescents with cancer often describe themselves as trying to be a good patient and good
child in making decisions in accord with how they believe a good patient and good child
would decide.
Among the challenges of caring for adolescents is the reality that the formative relational
influences in adolescents' decision-making are both complex and unique due to adolescent
patients' social networks and relational roles. Delineating adolescents' definitions of
being a good patient, a good child, a good sibling, and a good friend may enable the care
team to better understand the formative decisional influences relevant to adolescents with
cancer. Expanding knowledge about the decision making constructs relevant to adolescents
with cancer and recognizing the role of these social constructs in medical interactions has
the potential for development of a comprehensive care model that methodically evaluates the
self-assessed decision making influences and needs of adolescents at various stages in
oncology care.
This qualitative construct-defining study represents an initial step in the development of
enhanced interventions for improved psychosocial support in this vulnerable population.
PRIMARY OBJECTIVES:
- Describe the ways relationships and social interactions may factor into adolescent
study participants' approach to decisions;
- By reports from adolescents with cancer, identify behaviors from members of the study
participants' social network that would be helpful to adolescents in fulfilling their
preferred role in medical decision-making and achieving the desired level of
participation in medical decision-making;
- Identify adolescent participants' preferred role in medical decision making.
SECONDARY OBJECTIVES:
- Develop definitions of being a "good" patient, child, sibling, and friend from
adolescent participant reports (will also welcome the study participant to self-declare
any additional relational constructs they may wish to report);
- Describe how the adolescent study participant believes his or her "good" patient,
child, sibling, and friend definition may have changed over time;
- Describe the self-assessed positive and negative aspects of trying to achieve the
meanings of the "good" patient, child, sibling, and friend constructs from adolescent
participant reports;
- Describe the actions of members of the study participant's social network which may
help the study participant reach his/her definition of being a "good" patient, child,
sibling, and friend.
Participants will participate in a one-time voice-recorded, face-to-face interview
consisting of open-ended questions. Completion of the interview is expected to take less
than one hour.
The qualitative interview consists of thirty open-ended questions for participants with no
siblings and thirty-eight open-ended questions for participants who have siblings. Questions
will be audio-recorded, face-to-face semi-structured in-depth interview format. Health
information will also be collected from medical records.
Expected accrual is 100 participants, 50 at each participating site. Accrual will be halted
when the study reaches qualitative theme saturation. For this study, saturation will occur
when three consecutive interviews fail to raise a new theme.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |